Vimarsana
Biggest News Aggregation in the World

Page 42 - Multilateral Instrument News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multilateral Instrument. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multilateral Instrument Today - Breaking & Trending Today

CoTec Holdings Corp. Announces Initial Closing of Non-Brokered Private ... - Vimarsana News

CoTec Holdings Corp. Announces Initial Closing of Non-Brokered Private ...

CoTec Holdings Corp. Announces Initial Closing of Non-Brokered Private ...

Guanajuato Silver Announces Brokered LIFE Offering of - Vimarsana News

Guanajuato Silver Announces Brokered LIFE Offering of

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 25, 2024...

IT News Online - Perk Labs Announces Closing of Non-Brokered Private Placements - Vimarsana News

IT News Online - Perk Labs Announces Closing of Non-Brokered Private Placements

Perk Labs Announces Closing of Non-Brokered Private Placements

CoTec Holdings Corp. Announces Initial Closing of Non-Brokered Private Placement - Vimarsana News

CoTec Holdings Corp. Announces Initial Closing of Non-Brokered Private Placement

26.04.2024 - NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (the 'Corporation') is pleased to announce that it has completed ... Seite 1

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order - Vimarsana News

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

HAMILTON, ON and BOSTON, April 25, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that